Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Cardiology"
DOI: 10.1001/jamacardio.2018.4566
Abstract: Importance In the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial, the anti-inflammatory monoclonal antibody canakinumab significantly reduced the risk of recurrent cardiovascular events in patients with previous myocardial infarction (MI) and high-sensitivity C-reactive protein (hs-CRP)… read more here.
Keywords: cost effectiveness; recurrent cardiovascular; canakinumab; cardiovascular events ... See more keywords
Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-94298-y
Abstract: Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated periodic… read more here.
Keywords: selective activation; antibody; canakinumab; autoinflammatory ... See more keywords
Canakinumab for the treatment of hyperimmunoglobulin D syndrome
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2019.1571410
Abstract: ABSTRACT Introduction: Mevalonate Kinase Deficiency (MKD) is a rare monogenic autoinflammatory disorder (AID) with autosomal recessive inheritance caused by mutations in the MVK gene. It includes hyperimmunoglobulinemia D syndrome (HIDS) and mevalonic aciduria (a severe… read more here.
Keywords: canakinumab; canakinumab treatment; hyperimmunoglobulin syndrome; treatment ... See more keywords
Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever.
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead128
Abstract: OBJECTIVES There is no consensus on canakinumab treatment tapering and discontinuation strategies in colchicine-resistant familial Mediterranean fever (FMF) patients. In this study, we aimed to establish a treatment management and discontinuation protocol in pediatric FMF… read more here.
Keywords: fmf patients; familial mediterranean; resistant familial; colchicine resistant ... See more keywords
Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2016-209335
Abstract: Objective To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Methods Blood samples were collected from… read more here.
Keywords: gene expression; expression; canakinumab; tumour necrosis ... See more keywords
Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-217155
Abstract: Background Inhibition of interleukin (IL)-1 represents a promising treatment option in adult-onset Still's disease (AOSD). Objective To investigate the efficacy and safety of canakinumab in patients with AOSD and active joint involvement by means of… read more here.
Keywords: onset still; adult onset; treatment; group ... See more keywords
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-217419
Abstract: Objectives To evaluate the long-term efficacy and safety of canakinumab to treat patients with colchicine-resistant familial Mediterranean fever (crFMF) during Epoch 4 (weeks 41 to 113) of the CLUSTER study. Methods Patients received open-label canakinumab… read more here.
Keywords: term efficacy; long term; safety; efficacy ... See more keywords
AB0971 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM A SINGLE-CENTER STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.5476
Abstract: Results from various phase 3 clinical studies have demonstrated the efficacy of canakinumab to treat patients with systemic juvenile idiopathic arthirtis (sJIA). However, limited information is available on the long-term efficacy and safety of this… read more here.
Keywords: none; canakinumab; none declared; efficacy ... See more keywords
OP0092 LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) – 30-MONTH DATA FROM THE RELIANCE REGISTRY
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.3716
Abstract: In clinical trials as well as in real-life, the IL-1ß inhibitor canakinumab leads to rapid remission of symptoms in the treatment of CAPS, a monogenic autoinflammatory disease with severe systemic and organ inflammation.The RELIANCE registry… read more here.
Keywords: grant research; sobi; canakinumab; consultant ... See more keywords
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/0008-5472.can-19-3176
Abstract: These findings suggest that targeting the IL1β inflammatory pathway might be critical in reducing tumor-promoting inflammation and lung cancer incidence. In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), inhibition of the IL1β inflammatory pathway by… read more here.
Keywords: canakinumab; lung cancer; cancer; cantos ... See more keywords
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Sign Up to like & getrecommendations! Published in 2019 at "Circulation"
DOI: 10.1161/circulationaha.118.038010
Abstract: Background: Subclinical inflammation is associated with an increased risk of heart failure and with adverse prognosis in patients with established heart failure. Yet, treatments specifically directed at reducing inflammation in patients with heart failure have… read more here.
Keywords: hospitalization heart; canakinumab; composite hhf; heart ... See more keywords